Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive … (NCT03038672) | Clinical Trial Compass
Active — Not RecruitingPhase 2
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
United States54 participantsStarted 2018-12-21
Plain-language summary
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as varlilumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients must have a histopathologically confirmed diagnosis of an aggressive B-cell non-Hodgkin lymphoma that is recurrent or refractory to standard therapy
* For the purpose of this study, aggressive B-cell NHL will be deemed any lymphoma belonging to one of the following groups according to the 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms
* For the purposes of stratification, diagnoses are grouped into 2 categories:
* Category A
* Burkitt lymphoma
* Burkitt-like lymphoma with 11q aberration
* High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
* High-grade B-cell lymphoma, not otherwise specified (NOS)
* Category B
* Diffuse large B-cell lymphoma (DLBCL), NOS
* Diffuse large B-cell lymphoma (DLBCL), NOS; germinal center B-cell type
* Diffuse large B-cell lymphoma (DLBCL), NOS; activated B-cell type
* Large B-cell lymphoma with IRF4 rearrangement
* T-cell/histiocyte-rich large B-cell lymphoma
* Primary DLBCL of the central nervous system (CNS)
* Primary cutaneous DLBCL, leg type
* Epstein-Barr virus (EBV)+ DLBCL, NOS
* EBV+ mucocutaneous ulcer
* DLBCL associated with chronic inflammation
* Lymphomatoid granulomatosis
* Primary mediastinal (thymic) large B-cell lymphoma
* Intravascular large B-cell lymphoma
* ALK+ large B-cell lymphoma
* Plasmablastic lymphoma
…